Development of PF-06671008, a Highly Potent Anti-P-Cadherin/Anti-Cd3 Bispecific DART Molecule With Extended Half-Life for the Treatment of Cancer
Antibodies - Switzerland
doi 10.3390/antib5010006
Full Text
Open PDFAbstract
Available in full text
Date
March 4, 2016
Authors
Publisher
MDPI AG